Fosun Pharma's (02196.HK) holding subsidiary's FXS887 tablets receive approval for clinical trials.

Sina Finance News, Fosun Pharma (02196.HK) announced that recently, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the "Company") subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (hereinafter referred to as "Fosun Pharmaceutical Industry") received approval from the National Medical Products Administration to conduct clinical trials on FXS887 tablets (project code and hereinafter referred to as "FXS0887") for advanced malignant solid tumors. Fosun Pharmaceutical Industry plans to conduct Phase I clinical trials of FXS0887 in China when conditions are met.